Novartis study shows real-world benefits of Entresto for heart failure

Novartis has announced the findings of a new real-world database study showing the benefits its drug Entresto can deliver for people with heart failure.

The non-interventional, retrospective database study examined changes in clinical characteristics of 1,643 German patients with heart failure and reduced ejection fraction receiving Entresto for 12 months after their first dose.

Entresto was shown to reverse the trend of worsening heart failure symptom, resulting in improved physical activity traits such as exercise and other daily activities at 90 and 180 days after treatment initiation.

The drug also significantly reduced levels of NT-proBNP, a key blood marker associated with cardiovascular risk in patients with heart failure, with the magnitude of the decrease similar to that observed in the earlier PARADIGM-HF study.

Additionally, it was shown that the majority of patients started and stayed on the lowest dose of Entresto.

Shreeram Aradhye, chief medical officer and global head of medical affairs at Novartis Pharmaceuticals, said: "We are excited to see the growing body of evidence showing that Entresto has a beneficial effect on the quality of life in heart failure, in addition to reducing cardiovascular death and heart failure hospitalisation."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.